Filip Dubovsky - 17 Jun 2024 Form 4 Insider Report for NOVAVAX INC (NVAX)

Signature
/s/Mark J. Casey, Attorney-in-Fact
Issuer symbol
NVAX
Transactions as of
17 Jun 2024
Net transactions value
-$201,164
Form type
4
Filing time
20 Jun 2024, 17:08:39 UTC
Previous filing
15 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise $9,786 +1,404 +2.1% $6.97 68,017 17 Jun 2024 Direct
transaction NVAX Common Stock Options Exercise $76,125 +12,500 +18% $6.09 80,517 17 Jun 2024 Direct
transaction NVAX Common Stock Sale $180,750 -12,500 -16% $14.46 68,017 17 Jun 2024 Direct
transaction NVAX Common Stock Sale $20,414 -1,404 -2.1% $14.54 66,613 17 Jun 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Stock Option (Right to Buy) Options Exercise $9,786 -1,404 -2.9% $6.97 46,324 17 Jun 2024 Common Stock 1,404 $6.97 Direct F1
transaction NVAX Stock Option (Right to Buy) Options Exercise $76,125 -12,500 -25% $6.09 37,500 17 Jun 2024 Common Stock 12,500 $6.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.